rich 1.0 Watch on YouTube (https://www.youtube.com/watch?v=xqSTbDZLALI) Andrew Catchpole, Chief Scientific Officer of hVIVO (https://www.voxmarkets.com/listings/HVO:LN)   joins Martin Luke of Vox Markets to discuss hVIVO’s newly signed £6 million influenza human challenge trial contract. Andrew explains how the study will evaluate a prophylactic antiviral treatment using hVIVO’s specialist influenza challenge model, highlighting the speed and efficiency advantages of human challenge trials, the growing focus on antiviral therapies, and why hVIVO continues to attract global clients. The Vox Markets Podcast https://audioboom.com/channels/5051662-the-vox-markets-podcast Audioboom https://audioboom.com 480 95 https://audioboom.com/i/40555564/600x600/c 600 600 <iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8900463/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>